
-
Viracta Therapeutics Inc OTC Markets OTCPK:VIRX Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Location: 2533 South Coast Highway 101, Cardiff, CA, 92007, United States | Website: https://www.viracta.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-3.51M
Cash
21.13M
Avg Qtr Burn
-8.699M
Short % of Float
0.79%
Insider Ownership
2.99%
Institutional Own.
21.26%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nana-val (nanatinostat + valganciclovir) Details Cancer, Diffuse large B cell lymphoma | Phase 2 Data readout | |
Nana-val (nanatinostat + valganciclovir) Details Cancer, Lymphoma | Phase 2 Data readout | |
Nana-val (Nanatinostat (VRx-3996) (histone deacetylase (HDAC) inhibitor) + valganciclovir) Details Solid tumor/s, Cancer, Nasopharyngeal carcinoma | Phase 2 Initiation |